Literature DB >> 2755873

Human glucagon and vasoactive intestinal polypeptide (VIP) stimulate free fatty acid release from human adipose tissue in vitro.

W O Richter1, H Robl, P Schwandt.   

Abstract

Glucagon, vasoactive intestinal polypeptide and secretin are strong stimulators of lipolysis in adipose tissue from laboratory animals. Yet, in human adipose tissue these data could not be confirmed under comparable experimental conditions. Using pH stat titration, an advanced in vitro test system for evaluating lipolysis, it was possible to demonstrate lipolytic activity for glucagon down to a concentration of 10(-8) mol/l. This is comparable to the minimal effective doses in rat adipose tissue and corresponds to the effect of equimolar concentrations of noradrenaline in man. Secretin with an amino acid sequence very similar to glucagon was not lipolytically active, while VIP stimulated free fatty acid release in a concentration of 10(-6) mol/l. Since the minimal effective dose of glucagon is only 30 times greater than the plasma levels a physiological significance of these finding may be suggested. The lipolytic activity of VIP seems to be only of pharmacological interest.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2755873     DOI: 10.1016/0196-9781(89)90039-9

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  14 in total

1.  Identification of the early VIP-regulated transcriptome and its associated, interactome in resting and activated murine CD4 T cells.

Authors:  Sheri Tinnell Dorsam; Emilie Vomhof-Dekrey; Rebecca J Hermann; Jodie S Haring; Travis Van der Steen; Erich Wilkerson; Goran Boskovic; James Denvir; Yulia Dementieva; Donald Primerano; Glenn Paul Dorsam
Journal:  Mol Immunol       Date:  2010-02-01       Impact factor: 4.407

2.  Oxytocin participates on the effects of vasoactive intestinal peptide on food intake and plasma parameters.

Authors:  Andressa B Martins; Marcela C Garnica-Siqueira; Dimas A M Zaia; Cássia Thaïs B V Zaia; Ernane T Uchôa
Journal:  Mol Cell Biochem       Date:  2017-07-27       Impact factor: 3.396

3.  Intraneural stimulation elicits an increase in subcutaneous interstitial glycerol levels in humans.

Authors:  C Dodt; P Lonnroth; H L Fehm; M Elam
Journal:  J Physiol       Date:  1999-12-01       Impact factor: 5.182

Review 4.  The metabolic actions of glucagon revisited.

Authors:  Kirk M Habegger; Kristy M Heppner; Nori Geary; Timothy J Bartness; Richard DiMarchi; Matthias H Tschöp
Journal:  Nat Rev Endocrinol       Date:  2010-10-19       Impact factor: 43.330

5.  Cross Talk Between Insulin and Glucagon Receptor Signaling in the Hepatocyte.

Authors:  Kirk M Habegger
Journal:  Diabetes       Date:  2022-09-01       Impact factor: 9.337

Review 6.  New Developments in Glucagon Treatment for Hypoglycemia.

Authors:  LesleAnn Hayward Story; Leah M Wilson
Journal:  Drugs       Date:  2022-08-06       Impact factor: 11.431

7.  Regulation of Appetite, Body Composition, and Metabolic Hormones by Vasoactive Intestinal Polypeptide (VIP).

Authors:  John P Vu; Muriel Larauche; Martin Flores; Leon Luong; Joshua Norris; Suwan Oh; Li-Jung Liang; James Waschek; Joseph R Pisegna; Patrizia M Germano
Journal:  J Mol Neurosci       Date:  2015-04-23       Impact factor: 3.444

Review 8.  Neural regulation of bone marrow adipose tissue.

Authors:  Xiao Zhang; Mohamed G Hassan; Erica L Scheller
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2021-03-15       Impact factor: 5.667

Review 9.  A compendium of G-protein-coupled receptors and cyclic nucleotide regulation of adipose tissue metabolism and energy expenditure.

Authors:  Ryan P Ceddia; Sheila Collins
Journal:  Clin Sci (Lond)       Date:  2020-03-13       Impact factor: 6.876

10.  Glucagon stimulates hepatic FGF21 secretion through a PKA- and EPAC-dependent posttranscriptional mechanism.

Authors:  Holly A Cyphert; Kimberly M Alonge; Siri M Ippagunta; F Bradley Hillgartner
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.